Psychological Intervention modifiEs Outcome of Patients With implAntable Cardioverter dEfibrillator: The PEACE Study (PEACE)

September 12, 2016 updated by: Centre Hospitalier Universitaire de Besancon
This study aims to investigate whether follow-up with a psychologist has an impact on the outcome of patients with an implantable automated defibrillator.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The implantation of an ICD in primary prevention is known to increase the rates of anxiety and depression, which can reach up to 45% and 35% respectively in this patient population. Several studies have reported that psychological accompaniment for these patients can alleviate the symptoms of anxiety and/or depression. Therefore, we aim to investigate the utility of psychological follow-up for a period of 1 year after first implantation of an ICD for primary prevention.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
18

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Besancon, France, 25000
        • CHU Besançon

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adult patients (aged 18 years or over)
  • indication for implantation of an ICD for primary prophylaxis
  • written informed consent provided
  • patients with social security coverage

Exclusion Criteria:

  • patients under legal tutorship or guardianship
  • patients with no social security coverage
  • patients still within the exclusion period after participation in another clinical trial, as indicated by the national registry of clinical trial volunteers
  • patients unable to complete the questionnaires (language barriers, mentally deficient, illiteracy or dementia)
  • patients awaiting heart transplant
  • patients who refuse to provide written informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Psychological follow-up
Patients undergoing implantation of an ICD for primary prevention will have an individual interview with a qualified psychologist in addition to standard medical follow-up.
Other: Individual interview with a qualified psychologist
Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
No Intervention: Control
Patients undergoing implantation of an ICD for primary prevention will have standard medical follow-up.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Mini International Neuropsychiatric Interview score
Time Frame: 48 hours after implantation
48 hours after implantation
Mini International Neuropsychiatric Interview score
Time Frame: 2 weeks after implantation
2 weeks after implantation
Mini International Neuropsychiatric Interview score
Time Frame: 2 months after implantation
2 months after implantation
Mini International Neuropsychiatric Interview score
Time Frame: 4 months after implantation
4 months after implantation
Mini International Neuropsychiatric Interview score
Time Frame: 6 months after implantation
6 months after implantation
Mini International Neuropsychiatric Interview score
Time Frame: 12 months after implantation
12 months after implantation

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Quality of life
Time Frame: 48 hours after implantation
Measure of patient's quality of life using the Short Form (SF) 36 item questionnaire
48 hours after implantation
Quality of life
Time Frame: 2 weeks after implantation
Measure of patient's quality of life using the Short Form (SF) 36 item questionnaire
2 weeks after implantation
Quality of life
Time Frame: 2 months after implantation
Measure of patient's quality of life using the Short Form (SF) 36 item questionnaire
2 months after implantation
Quality of life
Time Frame: 4 months after implantation
Measure of patient's quality of life using the Short Form (SF) 36 item questionnaire
4 months after implantation
Quality of life
Time Frame: 6 months after implantation
Measure of patient's quality of life using the Short Form (SF) 36 item questionnaire
6 months after implantation
Quality of life
Time Frame: 12 months after implantation
Measure of patient's quality of life using the Short Form (SF) 36 item questionnaire
12 months after implantation
State-Trait Anxiety Inventory
Time Frame: 48 hours after implantation
Measure of state and trait anxiety
48 hours after implantation
State-Trait Anxiety Inventory
Time Frame: 2 weeks after implantation
Measure of state and trait anxiety
2 weeks after implantation
State-Trait Anxiety Inventory
Time Frame: 2 months after implantation
Measure of state and trait anxiety
2 months after implantation
State-Trait Anxiety Inventory
Time Frame: 4 months after implantation
Measure of state and trait anxiety
4 months after implantation
State-Trait Anxiety Inventory
Time Frame: 6 months after implantation
Measure of state and trait anxiety
6 months after implantation
State-Trait Anxiety Inventory
Time Frame: 12 months after implantation
Measure of state and trait anxiety
12 months after implantation
Minnesota Living with Heart Failure questionnaire
Time Frame: 48 hours after implantation
Evaluation of the quality of life in patients with heart failure
48 hours after implantation
Minnesota Living with Heart Failure questionnaire
Time Frame: 2 weeks after implantation
Evaluation of the quality of life in patients with heart failure
2 weeks after implantation
Minnesota Living with Heart Failure questionnaire
Time Frame: 2 months after implantation
Evaluation of the quality of life in patients with heart failure
2 months after implantation
Minnesota Living with Heart Failure questionnaire
Time Frame: 4 months after implantation
Evaluation of the quality of life in patients with heart failure
4 months after implantation
Minnesota Living with Heart Failure questionnaire
Time Frame: 6 months after implantation
Evaluation of the quality of life in patients with heart failure
6 months after implantation
Minnesota Living with Heart Failure questionnaire
Time Frame: 12 months after implantation
Evaluation of the quality of life in patients with heart failure
12 months after implantation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Centre Hospitalier Universitaire de Besancon

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Alexandre Guignier, MD, Centre Hospitalier Universitaire de Besancon

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2014

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
August 1, 2016

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2016

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 1, 2016

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 12, 2016

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
September 15, 2016

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 15, 2016

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 12, 2016

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2016

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • P/2014/217

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings